
Edgewise Therapeutics, Inc.: shareholders and insiders
Price
$41.17
November 19, 2026Market cap $4.4B
What Ploutos Investor adds for Edgewise Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 18, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$18M
7 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan89%
- The rest11%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $18M by 7 people
- 2025: no buys, no sales
- 2026: no buys, sold $18M by 7 people
- Nov 16, 2026Joanne M. DonovanCMOKind10b5-1
- Nov 10, 2026Michael NofiChief Financial OfficerKind
- Nov 10, 2026Michael NofiChief Financial OfficerKind
- Oct 1, 2026Jonathan C FoxDirectorKind
- Aug 13, 2026Joanne M. DonovanCMOKind10b5-1
- Aug 12, 2026Joanne M. DonovanCMOKind
- Aug 12, 2026Joanne M. DonovanCMOKind
- Aug 12, 2026Joanne M. DonovanCMOKind
- Aug 12, 2026Joanne M. DonovanCMOKind
- Aug 12, 2026Joanne M. DonovanCMOKind
- Aug 12, 2026Joanne M. DonovanCMOKind
- Aug 12, 2026Alan J RussellChief Scientific OfficerKind
- Aug 12, 2026Alan J RussellChief Scientific OfficerKind
- Aug 12, 2026Alan J RussellChief Scientific OfficerKind
- Aug 12, 2026Alan J RussellChief Scientific OfficerKind
- Aug 12, 2026Alan J RussellChief Scientific OfficerKind
- Aug 12, 2026John R MooreGeneral CounselKind
- Aug 12, 2026John R MooreGeneral CounselKind
- Aug 12, 2026John R MooreGeneral CounselKind
- Aug 12, 2026John R MooreGeneral CounselKind
- Aug 12, 2026John R MooreGeneral CounselKind
- Aug 12, 2026John R MooreGeneral CounselKind
- Aug 12, 2026Behrad DerakhshanChief Business OfficerKind
- Aug 12, 2026Behrad DerakhshanChief Business OfficerKind
- Aug 12, 2026Behrad DerakhshanChief Business OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Joanne M. DonovanCMO | 10b5-1 | 854 | $45.48 | $38.8K | Form 4 |
| Nov 10, 2026 | Michael NofiChief Financial Officer | 10.9K | – | – | Form 4 | |
| Nov 10, 2026 | Michael NofiChief Financial Officer | 4,442 | $45.43 | $201.8K | Form 4 | |
| Oct 1, 2026 | Jonathan C FoxDirector | 308 | – | – | Form 4 | |
| Aug 13, 2026 | Joanne M. DonovanCMO | 10b5-1 | 2,919 | $43.41 | $126.7K | Form 4 |
| Aug 12, 2026 | Joanne M. DonovanCMO | 5,781 | – | – | Form 4 | |
| Aug 12, 2026 | Joanne M. DonovanCMO | 7,031 | – | – | Form 4 | |
| Aug 12, 2026 | Joanne M. DonovanCMO | 2,839 | $43.78 | $124.3K | Form 4 | |
| Aug 12, 2026 | Joanne M. DonovanCMO | 2,779 | $43.71 | $121.5K | Form 4 | |
| Aug 12, 2026 | Joanne M. DonovanCMO | 104 | $44.43 | $4.6K | Form 4 | |
| Aug 12, 2026 | Joanne M. DonovanCMO | 800 | $44.52 | $35.6K | Form 4 | |
| Aug 12, 2026 | Alan J RussellChief Scientific Officer | 5,781 | – | – | Form 4 | |
| Aug 12, 2026 | Alan J RussellChief Scientific Officer | 7,031 | – | – | Form 4 | |
| Aug 12, 2026 | Alan J RussellChief Scientific Officer | 3,238 | $43.68 | $141.4K | Form 4 | |
| Aug 12, 2026 | Alan J RussellChief Scientific Officer | 2,273 | $43.68 | $99.3K | Form 4 | |
| Aug 12, 2026 | Alan J RussellChief Scientific Officer | 390 | $44.46 | $17.3K | Form 4 | |
| Aug 12, 2026 | John R MooreGeneral Counsel | 5,781 | – | – | Form 4 | |
| Aug 12, 2026 | John R MooreGeneral Counsel | 6,718 | – | – | Form 4 | |
| Aug 12, 2026 | John R MooreGeneral Counsel | 2,439 | $43.81 | $106.8K | Form 4 | |
| Aug 12, 2026 | John R MooreGeneral Counsel | 59 | $44.41 | $2.6K | Form 4 | |
| Aug 12, 2026 | John R MooreGeneral Counsel | 99 | $44.50 | $4.4K | Form 4 | |
| Aug 12, 2026 | John R MooreGeneral Counsel | 2,419 | $43.80 | $105.9K | Form 4 | |
| Aug 12, 2026 | Behrad DerakhshanChief Business Officer | 5,781 | – | – | Form 4 | |
| Aug 12, 2026 | Behrad DerakhshanChief Business Officer | 7,500 | – | – | Form 4 | |
| Aug 12, 2026 | Behrad DerakhshanChief Business Officer | 2,171 | $43.79 | $95.1K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 16, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by EWTX's officers and directors from 2021 up to November 18, 2025, 5 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Orbimed Advisorswith 3 more personsShare of class14.5%
- Paradigm BioCapital Advisors LPwith 3 more personsShare of class9.50%
- RA Capital Management, L.P.with 3 more personsShare of class7.80%
- BlackRock, Inc.Share of class5.50%
- Janus Henderson GroupShare of class5.50%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Orbimed Advisorswith 3 more persons | 14.5% | 15.25M | May 12, 2025 | 13D/A | |
| Paradigm BioCapital Advisors LPwith 3 more persons | 9.50% | 10.22M | Aug 14, 20263 filings since Feb 3, 2025 | 13G/A | |
| RA Capital Management, L.P.with 3 more persons | 7.80% | 8.39M | Aug 14, 20262 filings since Nov 14, 2025 | 13G/A | |
| BlackRock, Inc. | 5.50% | 5.82M | Jul 17, 2025 | 13G/A | |
| Janus Henderson Group | 5.50% | 5.92M | May 15, 20265 filings since Feb 14, 2025 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Orbimed Advisors14.5%From the filing of May 12, 2025
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the…
From the filing of May 12, 2025
Fell to 5% or less (4)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+447%
- Point72 (Cohen)In the quarter
- Millennium Mgmt (Englander)In the quarter
- D.E. ShawIn the quarter-64%
- AQR CapitalIn the quarter×13.7
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 2.57M | +447% | $104M | 0.06% |
| Point72 (Cohen) | – | – | 0.01% | |
| Millennium Mgmt (Englander) | 33.5K | $1.4M | 0.00% | |
| D.E. Shaw | 68.5K | -64% | $2.8M | 0.00% |
| AQR Capital | 253.4K | ×13.7 | $10M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 11.0% of its shares outstanding were held short, +4.7% since the report before.
- Shares held short
- 11.75M
- 11.0%
- Since the report before11.22M on Sep 30, 2026
- +4.7%
- 8.5
- 1.39M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 86%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 6.01M
- Nov 15, 2023: Shares held short 6.33M
- Nov 30, 2023: Shares held short 7.03M
- Dec 15, 2023: Shares held short 8.50M
- Dec 29, 2023: Shares held short 9.34M
- Jan 12, 2024: Shares held short 8.17M
- Jan 31, 2024: Shares held short 5.40M
- Feb 15, 2024: Shares held short 5.13M
- Feb 29, 2024: Shares held short 5.46M
- Mar 15, 2024: Shares held short 4.48M
- Mar 28, 2024: Shares held short 5.72M
- Apr 15, 2024: Shares held short 5.76M
- Apr 30, 2024: Shares held short 6.52M
- May 15, 2024: Shares held short 6.59M
- May 31, 2024: Shares held short 6.50M
- Jun 14, 2024: Shares held short 7.62M
- Jun 28, 2024: Shares held short 8.48M
- Jul 15, 2024: Shares held short 8.58M
- Jul 31, 2024: Shares held short 8.08M
- Aug 15, 2024: Shares held short 6.40M
- Aug 30, 2024: Shares held short 7.78M
- Sep 13, 2024: Shares held short 8.17M
- Sep 30, 2024: Shares held short 9.34M
- Oct 15, 2024: Shares held short 8.49M
- Oct 31, 2024: Shares held short 7.29M
- Nov 15, 2024: Shares held short 6.39M
- Nov 29, 2024: Shares held short 5.74M
- Dec 13, 2024: Shares held short 5.64M
- Dec 31, 2024: Shares held short 6.14M
- Jan 15, 2025: Shares held short 6.74M
- Jan 31, 2025: Shares held short 7.06M
- Feb 14, 2025: Shares held short 8.06M
- Feb 28, 2025: Shares held short 8.73M
- Mar 14, 2025: Shares held short 9.09M
- Mar 31, 2025: Shares held short 10.39M
- Apr 15, 2025: Shares held short 12.85M
- Apr 30, 2025: Shares held short 13.26M
- May 15, 2025: Shares held short 12.68M
- May 30, 2025: Shares held short 14.31M
- Jun 13, 2025: Shares held short 12.53M
- Jun 30, 2025: Shares held short 12.66M
- Jul 15, 2025: Shares held short 11.07M
- Jul 31, 2025: Shares held short 10.19M
- Aug 15, 2025: Shares held short 10.22M
- Aug 29, 2025: Shares held short 10.09M
- Sep 15, 2025: Shares held short 8.57M
- Sep 30, 2025: Shares held short 7.31M
- Oct 15, 2025: Shares held short 8.62M
- Oct 31, 2025: Shares held short 9.51M
- Nov 14, 2025: Shares held short 10.05M
- Nov 28, 2025: Shares held short 11.15M
- Dec 15, 2025: Shares held short 10.52M
- Dec 31, 2025: Shares held short 11.69M
- Jan 15, 2026: Shares held short 9.42M
- Jan 30, 2026: Shares held short 9.49M
- Feb 13, 2026: Shares held short 9.49M
- Feb 27, 2026: Shares held short 9.48M
- Mar 13, 2026: Shares held short 9.48M
- Mar 31, 2026: Shares held short 9.45M
- Apr 15, 2026: Shares held short 10.08M
- Apr 30, 2026: Shares held short 10.13M
- May 15, 2026: Shares held short 10.35M
- May 29, 2026: Shares held short 10.91M
- Jun 15, 2026: Shares held short 9.93M
- Jun 30, 2026: Shares held short 10.49M
- Jul 15, 2026: Shares held short 10.07M
- Jul 31, 2026: Shares held short 9.84M
- Aug 14, 2026: Shares held short 9.68M
- Aug 31, 2026: Shares held short 9.35M
- Sep 15, 2026: Shares held short 9.54M
- Sep 30, 2026: Shares held short 11.22M
- Oct 15, 2026: Shares held short 11.75M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading58.3% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 58.3% of the shares in the reported trades were short sales, against 56.8% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 58.3%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 56.8%
- Change
- +1.5 pts
- Short sales a dayon average, of 741.6K shares
- 432.3K
- More than atof 3,656 US-listed companies, same days
- 78%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 46.3%
- Oct 13, 2026: Short sales 58.6%
- Oct 14, 2026: Short sales 63.4%
- Oct 15, 2026: Short sales 71.1%
- Oct 16, 2026: Short sales 46.5%
- Oct 19, 2026: Short sales 21.9%
- Oct 20, 2026: Short sales 62.4%
- Oct 21, 2026: Short sales 74.9%
- Oct 22, 2026: Short sales 67%
- Oct 23, 2026: Short sales 62%
- Oct 26, 2026: Short sales 58.1%
- Oct 27, 2026: Short sales 21%
- Oct 28, 2026: Short sales 73.9%
- Oct 29, 2026: Short sales 42.9%
- Oct 30, 2026: Short sales 49.7%
- Nov 2, 2026: Short sales 57.4%
- Nov 3, 2026: Short sales 71.8%
- Nov 4, 2026: Short sales 48.5%
- Nov 5, 2026: Short sales 63.7%
- Nov 6, 2026: Short sales 70.2%
- Nov 9, 2026: Short sales 46.8%
- Nov 10, 2026: Short sales 49.9%
- Nov 11, 2026: Short sales 53.5%
- Nov 12, 2026: Short sales 77%
- Nov 13, 2026: Short sales 53.4%
- Nov 16, 2026: Short sales 41.8%
- Nov 17, 2026: Short sales 35.2%
- Nov 18, 2026: Short sales 57.9%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- OrbiMed Genesis GP LLCDirector,TenPercentOwnerDirectly–
- OrbiMed Capital GP VI LLCDirector,TenPercentOwnerDirectly–
- Peter A. ThompsonDirector,TenPercentOwnerDirectly–
- Badreddin EdrisDirectorDirectly96.8K
- R Michael CarruthersChief Financial OfficerDirectly86.2K
- Kevin KochPresident and CEODirectly52.5K
- Behrad DerakhshanChief Business OfficerDirectly34.8K
- Alan J RussellChief Scientific OfficerDirectly31.9K
- Jonathan C FoxDirectorDirectly25.1K
- John R MooreGeneral CounselDirectly17.7K
- Joanne M. DonovanCMODirectly8,139
- Marc SemigranChief Development OfficerDirectly6,716
- Michael NofiChief Financial OfficerDirectly6,495
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| OrbiMed Genesis GP LLCDirector,TenPercentOwner | – | 14.81M | Apr 3, 2025 | Form 4 |
| OrbiMed Capital GP VI LLCDirector,TenPercentOwner | – | 14.44M | Jan 23, 2024 | Form 4 |
| Peter A. ThompsonDirector,TenPercentOwner | – | 443.8K | Apr 3, 2025 | Form 4 |
| Badreddin EdrisDirector | 96.8K | – | Jan 21, 2026 | Form 4 |
| R Michael CarruthersChief Financial Officer | 86.2K | – | Aug 12, 2025 | Form 4 |
| Kevin KochPresident and CEO | 52.5K | – | Aug 12, 2026 | Form 4 |
| Behrad DerakhshanChief Business Officer | 34.8K | – | Aug 12, 2026 | Form 4 |
| Alan J RussellChief Scientific Officer | 31.9K | – | Aug 12, 2026 | Form 4 |
| Jonathan C FoxDirector | 25.1K | – | Oct 1, 2026 | Form 4 |
| John R MooreGeneral Counsel | 17.7K | – | Aug 12, 2026 | Form 4 |
| Joanne M. DonovanCMO | 8,139 | – | Nov 16, 2026 | Form 4 |
| Marc SemigranChief Development Officer | 6,716 | – | Dec 24, 2024 | Form 4 |
| Michael NofiChief Financial Officer | 6,495 | – | Nov 10, 2026 | Form 4 |
A lower bound: it counts only the 13 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHEiShares U.S. Pharmaceuticals ETFWeight in the fund0.70%
- IBBiShares Biotechnology ETFWeight in the fund0.25%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.17%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.16%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.10%
- IWMiShares Russell 2000 ETFWeight in the fund0.09%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.07%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.04%
- VXFVanguard Extended Market Index FundWeight in the fund0.04%
- VHTVanguard Health Care Index FundWeight in the fund0.03%
17 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 175
- Q4 2025: Managers 200
- Q1 2026: Managers 216
- Q2 2026: Managers 225
Institutional investors by quarter
The fund managers holding EWTX, quarter by quarter, from Q1 2021 to Q2 2025, 18 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 225 managers held 119M shares, worth $4.8B. During the quarter 41 opened a position, 32 closed one, 79 added and 74 trimmed.
The largest holders, Q2 2026
- Orbimed AdvisorsIn the quarter
- Paradigm Biocapital AdvisorsIn the quarter+39%
- Ra Capital ManagementIn the quarter-20%
- BlackRockIn the quarter+2.1%
- Jupiter TopcoIn the quarter
- FMRIn the quarter+440%
- Novo Holdings A/sIn the quarter
- Driehaus Capital ManagementIn the quarter+5.6%
- Perceptive AdvisorsIn the quarter-1.1%
- Vanguard Capital ManagementIn the quarter+1.9%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Orbimed Advisors | 15.52M | $631M | |
| Paradigm Biocapital Advisors | 10.22M | +39% | $415M |
| Ra Capital Management | 8.39M | -20% | $341M |
| BlackRock | 6.61M | +2.1% | $268M |
| Jupiter Topco | 6.08M | $247M | |
| FMR | 5.49M | +440% | $223M |
| Novo Holdings A/s | 5.35M | $217M | |
| Driehaus Capital Management | 4.73M | +5.6% | $192M |
| Perceptive Advisors | 4.37M | -1.1% | $178M |
| Vanguard Capital Management | 3.86M | +1.9% | $157M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Edgewise Therapeutics's filings show?
Who buys and sells is one part of Edgewise Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have EWTX's insiders bought or sold?
From Jun 16, 2026 to Nov 18, 2026 Edgewise Therapeutics's insiders bought 0 and sold $10M of shares on the market. 80% of the sales were under set 10b5-1 plans.
Which well-known managers hold EWTX?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $104M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.